Synthesis, characterization and immunological properties of Escherichia coli 0157:H7 lipopolysaccharide- diphtheria toxoid conjugate vaccine
Abstract
Background and Objective: Escherichia coli O157:H7, an emerging pathogen, causes severe enteritis and the extraintestinal complication of hemolytic-uremic syndrome. The goal of this study was to evaluate the conjugate of E. coli O157: H7 lipopolysaccharide (LPS) with diphtheria toxoid (DT) as a candidate vaccine in mice model.
Material and Methods: LPS from E. coli O157:H7 was extracted by hot phenol method and then detoxified. Purified LPS was coupled to DT with adipic acid dihydrazide (ADH) as a spacer and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) as a linker. The coupling molar ratio of LPS to DT was 3:1. Clinical evaluation of E. coli O157:H7 LPS-DT conjugate was also performed.
Results: The conjugate was devoid of endotoxin activity and indicated 0.125 U/ml of D-LPS. Mice immunization with D-LPS DT conjugate elicited fourfold higher IgG antibody in comparison to D-LPS. Also, in vivo protection of mice with conjugate provided high protection against the LD50 of E. coli O157:H7, which indicated a good correlation with the IgG titer.
Conclusion: Our results showed that the suggested vaccine composed of E. coli O157:H7 LPS and DT had a significant potential to protect against E. coli infections.
Haack JP, Jelacic S, Besser TE, Weinberger E, Kirk D J, Mckee GL, et al. Escherichia coli O157 exposure in Wyoming and Seattle: serologic evidence of rural risk. Emerg Infect Dis 2013; 9: 1226-1231.
Shekl V, Mohawk KL, Brien ADO. Mouse models of Escherichia coli O157:H7 infection and Shiga toxin in- jection. J Biomed Biotech 2011; 2: 1-17.
Bansal TP, Jesudhasan S, Pillai T, Wood K, Jayaraman A. Temporal regulation of enterohemorrhagic Esche-richia coli virulence mediated by autoinducer-2. Appl Microbiol Biotechnol 2008; 78: 811–819.
Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-pro- ducing Escherichia coli and haemolytic uraemic syn- drome. Lancet 2005; 365: 1073–1086.
Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SHC.Safety and immunogenicity of Escherichia coli O157 a-specific polysaccharide conjugate vaccine in 2-5-year-old children. J Infect Dis 2006; 193:515-521.
Konadu E, B. Robbins J, Shiloach J, Bryla D, Szu SHC.Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-Specific polysaccharide- protein conjugate vaccines. Infect Immun 1994; 62: 5048-5054.
Konadu EY, Parke JC, Tran HT, Bryla DA, Robbins JB, Szu SHC. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 specific polysaccha- ride–Pseudomonas aeruginosa recombinant exopro- tein a conjugates in adults. J Infect Dis 1998; 177:383–387.
Konadu E, Rolfe AD, Calderwood S B, Pozsgay V, Shiloach J, Robbins JB, et al. Syntheses and immunologic properties of Escherichia coli O157 O-Specific polysaccharide and Shiga Toxin 1 B subunit conjugates in mice. Infect Immun 1994; 67: 6191–6193.
Said AA, Livermore DM, Williams JR. Expression of H1 outer-membrane protein of Pseudornonas aerugi- nosa in relation to sensitivity to EDTA and polymyxin B. J Med Microbiol 1987; 24: 267-274.
Rezania S, Amirmozaffari N, Tabarraei B, Jeddi-Teh- rani M, Zarei O, Alizadeh R, et al. Extraction, puri- fication and characterization of lipopolysaccharide from Escherichia coli and Salmonella typhi. Avicenna J Med Biotech 2011; 3: 3-9.
Kashef N, Behzadian-Nejad Q, Najar-Peerayen Sh, Mousavi-Hosseini K, Moazeni M, Rezvan H, et al. Preliminary investigation on the isolation of alginate produced by mucoid Pseudomonas aeruginosa. An-nals Microbiol 2005; 55: 279-282.
Kashef N, Behzadian-Nejad Q, Najar-Peerayeh Sh, Mousavi-Hosseini K, Moazzeni M, Djavid E. Synthe- sis and characterization of Pseudomonas aeruginosa alginate–tetanus toxoid conjugate. J Med Microbiol 2006; 55: 1441–1446.
Goldstein J, Hoffman T, Frasch C, Lizzio E F, Bein- ing PR, Hochstein D, et al. Lipopolysaccharide (LPS) from Brucella abortus is less toxic than that from Escherichia coli, suggesting the possible use of B. abortus or LPS from B. abortus as a carrier in vac- cines. Infect Immun 1992; 60: 1385-1389.
Cryz S J, Sadoff J C, Fürer E, Germanier R. Pseudo- monas aeruginosa polysaccharide-tetanus toxoid con- jugate vaccine: safety and immunogenicity in humans. J Infect Dis 1986; 154: 682-689.
Hudson L, Hay F C. 1989. Practical Immunology.Black well scientific pub. 3th ed.
Cryz S J, Fürer E, Cross AS, Wegmann A, Germanier R, Sadoff J C. Safety and immunogenicity of a Pseu- domonas aeruginosa O-polysaccharide toxin A conju- gate vaccine in humans. J Clin Invest 1987; 80: 51-56.
Fernández SV, Balbin YV, Calderón J, Icart LP, Ben- como V. Polysaccharide-Based Vaccines. Glycosci- ence 2008; 2700:27-23.
AI-Zeer M, Masoud H. LPS-based conjugate vaccines composed of O-polysaccharide from Pseudomonas aeruginosa IATS 6 and 11 bound to a carrier protein. World J Microbiol Biotechnol 2007; 23: 1541-1549.
Midwinter A, Faine S, Adler B. Vaccination of mice with lipopolysaccharide (LPS) and LPS-derived im- muno-conjugates from Leptospira interrogans. J Med Microbiol 1990; 33: 199-204.
Becket RS. Conjugate vaccines: practice and theory.Springer Semin Immunopathol 1993; 15:217-226.
Collier L, Balows A, Sussman M. Topley and Wilson's microbiology and microbial infections, 9th ed, 1998.
| Files | ||
| Issue | Vol 7 No 3 (2015) | |
| Section | Articles | |
| Keywords | ||
| Escherichia coli O157 H7 Conjugate vaccine Lipopolysaccharide (LPS) Diphtheria toxoid (DT) | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
